Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CAR T cells produced in vivo to treat cardiac injury
Joel G. Rurik, István Tombácz, Amir Yadegari, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 91-96
Open Access | Times Cited: 794

Showing 1-25 of 794 citing articles:

Natural killer cells in antitumour adoptive cell immunotherapy
Tamara Laskowski, Alexander Biederstädt, Katayoun Rezvani
Nature reviews. Cancer (2022) Vol. 22, Iss. 10, pp. 557-575
Open Access | Times Cited: 482
CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 347
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies
Stefan Frantz, Moritz Hundertmark, Jeanette Schulz‐Menger, et al.
European Heart Journal (2022) Vol. 43, Iss. 27, pp. 2549-2561
Open Access | Times Cited: 316
The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 312
Unlocking the promise of mRNA therapeutics
Eduarde Rohner, Ran Yang, Kylie S. Foo, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 11, pp. 1586-1600
Open Access | Times Cited: 306
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Sean A. Dilliard, Daniel J. Siegwart
Nature Reviews Materials (2023) Vol. 8, Iss. 4, pp. 282-300
Open Access | Times Cited: 304
Therapeutic in vivo delivery of gene editing agents
Aditya Raguram, Samagya Banskota, David R. Liu
Cell (2022) Vol. 185, Iss. 15, pp. 2806-2827
Open Access | Times Cited: 294
The landscape of aging
Yusheng Cai, Wei Song, Jiaming Li, et al.
Science China Life Sciences (2022) Vol. 65, Iss. 12, pp. 2354-2454
Open Access | Times Cited: 243
CAR T therapy beyond cancer: the evolution of a living drug
Daniel Baker, Zoltàn Arany, Joseph A. Baur, et al.
Nature (2023) Vol. 619, Iss. 7971, pp. 707-715
Closed Access | Times Cited: 242
mRNA-based cancer therapeutics
Chuang LIU, Qiangqiang Shi, Xiangang Huang, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 8, pp. 526-543
Closed Access | Times Cited: 226
Engineered cellular immunotherapies in cancer and beyond
Amanda Finck, Tatiana Blanchard, Christopher P. Roselle, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 678-689
Open Access | Times Cited: 209
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Yan Zong, Yi Lin, Tuo Wei, et al.
Advanced Materials (2023) Vol. 35, Iss. 51
Closed Access | Times Cited: 187
From bench to bedside: the history and progress of CAR T cell therapy
Aroshi Mitra, Amrita Barua, Luping Huang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 186
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 182
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 165
In vivo hematopoietic stem cell modification by mRNA delivery
Laura Breda, Tyler E. Papp, Michael Triebwasser, et al.
Science (2023) Vol. 381, Iss. 6656, pp. 436-443
Open Access | Times Cited: 153
The future of engineered immune cell therapies
Darrell J. Irvine, Marcela V. Maus, David Mooney, et al.
Science (2022) Vol. 378, Iss. 6622, pp. 853-858
Open Access | Times Cited: 122
Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency
Miffy H. Y. Cheng, Jerry Leung, Yao Zhang, et al.
Advanced Materials (2023) Vol. 35, Iss. 31
Open Access | Times Cited: 101
Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
Jilian R. Melamed, Saigopalakrishna S. Yerneni, Mariah L. Arral, et al.
Science Advances (2023) Vol. 9, Iss. 4
Open Access | Times Cited: 98
The Past, Present, and Future of Non-Viral CAR T Cells
Alex Moretti, Marianna Ponzo, Charles A. Nicolette, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 96
CAR-based therapies: opportunities for immuno-medicine beyond cancer
Haig Aghajanian, Joel G. Rurik, Jonathan A. Epstein
Nature Metabolism (2022) Vol. 4, Iss. 2, pp. 163-169
Open Access | Times Cited: 91
Targeted modulation of immune cells and tissues using engineered biomaterials
Parisa Yousefpour, Kaiyuan Ni, Darrell J. Irvine
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 2, pp. 107-124
Open Access | Times Cited: 85
In vivo human T cell engineering with enveloped delivery vehicles
Jennifer Hamilton, Evelyn Chen, Barbara S. Perez, et al.
Nature Biotechnology (2024) Vol. 42, Iss. 11, pp. 1684-1692
Open Access | Times Cited: 84
RNA therapeutics: updates and future potential
Caroline Zhang, Biliang Zhang
Science China Life Sciences (2022) Vol. 66, Iss. 1, pp. 12-30
Open Access | Times Cited: 83
Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications
Saiyang Xie, Si‐Chi Xu, Wei Deng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 77
Page 1 - Next Page

Scroll to top